Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program

Diabetes Care

Volumn 32, Issue 5, 2009, Pages 915-920

  Preiss, David ^a   Zetterstrand, Sofia ^b   McMurray, John J V ^a   Östergren, Jan ^c   Michelson, Eric L ^d   Granger, Christopher B ^e   Yusuf, Salim ^f   Swedberg, Karl ^g   Pfeffer, Marc A ^h   Gerstein, Hertzel C ⁱ   Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d ASTRAZENECA   (United Kingdom)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f Ontario Canada   (Canada)

^g UNIVERSITY OF GOTHENBURG   (Sweden)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; NITRATE; SPIRONOLACTONE;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DIURETIC THERAPY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; RISK ASSESSMENT; RISK FACTOR;

AGED; BLOOD PRESSURE; BODY MASS INDEX; CHRONIC DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, STATISTICAL; ODDS RATIO; REGRESSION ANALYSIS; SMOKING; VENTRICULAR FUNCTION, LEFT;

EID: 65949115714     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1709     Document Type: Article

References (25)

1. MacDonald MR, Petrie MC, Hawkins NM, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008;29:1224-1240
2. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes. Diabetes Care 2004;27:1879-1884
3. Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007;115:1371-1375
4. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure. Eur Heart J 2008;29:1377-1385
5. Stevens J, Couper D, Pankow J, et al. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res 2001;9:696-705
6. Dankner R, Abdul-Ghani MA, Gerber Y, et al. Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev 2007;23:551-558
7. Pradhan AD, Rifai N, Buring JE, et al. Hemoglobin a1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med 2007;120:720-727
8. Little RR, England JD, Wiedmeyer HM, et al. Glycated hemoglobin predicts progression to diabetes-mellitus in Pima-Indians with impaired glucose-tolerance. Diabetologia 1994;37:252-256
9. Norberg M, Eriksson JW, Lindahl B, et al. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed. J Intern Med 2006;260:263-271 (Pubitemid 44253640)
10. Griffin SJ, Little PS, Hales CN, et al. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000;16:164-171
11. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:48-53
12. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766
13. McMurray JJV, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771 (Pubitemid 37093916)
14. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-776 (Pubitemid 37093917)
15. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMP-reserved Trial. Lancet 2003;362:777-781 (Pubitemid 37093918)
16. Geiss LS, Pan LP, Cadwell B, et al. Changes in incidence of diabetes in US adults, 1997-2003. Am J Prev Med 2006;30:371-377
17. Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure. Arch Intern Med 2008;168:1699-1704
18. Saudek CD, Herman WH, Sacks DB, et al. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008;93:2447-2453
19. Jick SS, Bradbury BD. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 2004;58:303-309 (Pubitemid 39209064)
20. Tenenbaum A, Motro M, Fisman EZ, et al. Functional class in patients with heart failure is associated with the development of diabetes.AmJ Med 2003;114:271-275
21. Amato L, Paolisso G, Cacciatore F, et al. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. Diabetes Metab 1997;23:213-218
22. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis. Lancet 2007;369:201-207 (Pubitemid 46111014)
23. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141-150
24. Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004;53:2855-2860
25. Doi Y, Kubo M, Yonemoto K, et al. Liver enzymes as a predictor for incident diabetes in a Japanese population: the Hisayama study. Obesity 2007;15:1841-1850